评估Glibenclamide在动脉瘤下arachnoid出血中功能恢复的疗效:随机对照试验的元分析
Luciano Falcão1, Pedro Antonio Lopes Gomes2, Rafael Andrade Sampaio Silva1
1Bahiana School of Medicine and Public Health, Brotas, Salvador, Bahia, Brazil.
Clinical neurology and neurosurgery
|March 19, 2025
概括
格利本克拉米德并没有改善结果,也没有减少脑下关节下出血 (SAH) 的并发症. 需要进一步的研究来确定其在治疗SAH患者中的作用,尽管它有可能导致脑.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 作为硫氨基酸受体1 (SUR1) 抑制剂的 Glibenclamide 在治疗脑 edem 和神经炎症方面表现有前途.
- 这项研究调查了其在改善功能结果和减少脑下关节下出血 (aSAH) 患者并发症方面的疗效.
研究的目的:
- 评估glibenclamide在改善下大脑底下出血 (aSAH) 后功能结果方面的有效性.
- 评估格利本克拉米德对降低aSAH患者死亡率,再出血和脑水症等并发症的影响.
主要方法:
- 使用PubMed,EMBASE和Web of Science进行了随机对照试验 (RCT) 的系统审查和元分析.
- 关键结局包括修改的兰金尺度 (mRS) 评分,死亡率,再出血风险,水头发病率和住院时间.
- 统计分析,包括风险比率和平均差异,使用基于异质性的随机或固定效应模型进行.
主要成果:
- 分析了4项涉及290名参与者的RCT.
- 在90天或180天的mRS得分,死亡率,再出血风险,水脑发病率或住院时间方面没有发现显著差异.
- 超回归表明,格利本克莱米德剂量和修改后的费舍尔尺度显著影响了mRS结果,而年龄,WFNS等级和亨特-赫斯尺度则没有.
结论:
- 目前的证据表明,glibenclamide不会显著改善aSAH的结果或减少并发症.
- 需要更大的,多中心的RCT,标准化方案和扩展后续检查,以最终确定glibenclamide在aSAH管理中的作用.
- 格利本克拉米德在治疗脑方面的潜力需要在经过精心设计的临床试验中进行进一步的研究.
更多相关视频
08:53Assessing Neuroprotective Effects of Glycyrrhizae Radix et Rhizoma Extract Using a Transient Middle Cerebral Artery Occlusion Mouse Model
Published on: December 9, 2018
7.3K
09:14Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
2.2K
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
139
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
139
Oral Hypoglycemic Agents: Glinides
120
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
120
Dipeptidyl Peptidase 4 Inhibitors
148
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
148
